<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812394</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-301-010</org_study_id>
    <nct_id>NCT02812394</nct_id>
  </id_info>
  <brief_title>A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet速 (Carbidopa-levodopa) Tablets</brief_title>
  <official_title>A Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet速 (Carbidopa-levodopa) Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, randomized, three-period cross-over pharmacokinetic
      evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered
      carbidopa/levodopa, in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine the relative bioavailability of two CVT-301 (dose
      levels 1 and 2) capsules compared with the Reference Listed Drug (RLD) on a per milligram
      basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>within 15min pre-dose (baseline) and specified time points up to and @ 24h post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve from time 0 to the concentration at 24 hours (AUC0-24h)</measure>
    <time_frame>within 15min pre-dose (baseline) and specified time points up to and @ 24h post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events (AEs) including Serious AEs</measure>
    <time_frame>up to 9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>CVT-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.
CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.
Sinemet速 (carbidopa/levodopa)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-301 (Dose Level 1)</intervention_name>
    <description>All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.</description>
    <arm_group_label>CVT-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-301 (Dose Level 2)</intervention_name>
    <description>All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.</description>
    <arm_group_label>CVT-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet速</intervention_name>
    <description>All subjects will receive carbidopa/levodopa tablets administered every 8 hours.</description>
    <arm_group_label>CVT-301</arm_group_label>
    <other_name>carbidopa/levodopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good general health as determined by medical history, physical examination,
             electrocardiogram (ECG), vital signs, and clinical laboratory evaluation;

          -  FEV1/FVC above the 5th percentile of the predicted normal distribution for age and
             gender;

          -  Body Mass Index (BMI) between 18 - 30 kg/m2

        Exclusion Criteria:

          -  No flu-like syndrome or other respiratory infections within 2 weeks prior to the
             Screening Visit;

          -  Negative drug and alcohol testing;

          -  Negative pregnancy test for female subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Oh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site #001</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Episodic motor fluctuations (OFF periods)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

